Infigratinib

Infigratinib
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS[2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Infigratinib is a kinase inhibitor that is FDA approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

• Confirm t*Confirm the presence of an FGFR2 fusion or rearrangement prior to initiation of treatment with TRUSELTIQ.
• Recommended dosage: 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Take on an empty stomach at least 1 hour before or 2 hours after food, at approximately the same time each day.
• Swallow capsules whole with a glass of water. Do not crush, chew or dissolve.
• Mild and Moderate Renal Impairment: The recommended dosage is 100 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Mild Hepatic Impairment: The recommended dosage is 100 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Moderate Hepatic Impairment: The recommended dosage is 75 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. he presence of an FGFR2 fusion or rearrangement prior to initiation of treatment with TRUSELTIQ.
• Recommended dosage: 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Take on an empty stomach at least 1 hour before or 2 hours after food, at approximately the same time each day.
• Swallow capsules whole with a glass of water. Do not crush, chew or dissolve.
• Mild and Moderate Renal Impairment: The recommended dosage is 100 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Mild Hepatic Impairment: The recommended dosage is 100 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Moderate Hepatic Impairment: The recommended dosage is 75 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.

25 mg: Hard gelatin capsule with a white opaque body and a gray opaque cap - imprinted with black text on the body – INFI 25mg 100 mg: Hard gelatin capsule with a white opaque body and a light orange opaque cap - imprinted with black text on the body – INFI 100mg

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Infigratinib in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Infigratinib in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Infigratinib FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Infigratinib in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Infigratinib in pediatric patients.

Contraindications

None.

Warnings

Ocular Toxicity

Retinal Pigment Epithelial Detachment (RPED)

• TRUSELTIQ can cause RPED, which may cause symptoms such as blurred vision.
• Among 351 patients who received TRUSELTIQ across clinical trials.

where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 11% of patients, including patients with asymptomatic RPED. The median time to first onset of RPED was 26 days. RPED led to dose interruption/reduction of TRUSELTIQ in 3.4% of patients, and permanent discontinuation in 0.6% of patients.

• Perform a comprehensive ophthalmic examination including OCT prior to initiation of TRUSELTIQ, at 1 month, at 3 months, and then every 3 months thereafter during treatment. Refer patients for ophthalmic evaluation urgently for onset of visual symptoms, and follow-up every 3 weeks until resolution or discontinuation of TRUSELTIQ.

Withhold TRUSELTIQ as recommended.

Dry Eye

Among 351 patients who received TRUSELTIQ across clinical trials,dry eye occurred in 29% of patients. Treat patients with ocular demulcents as needed.

====Hyperphosphatemia and Soft Tissue Mineralization====

• TRUSELTIQ can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcinosis, non-uremic calciphylaxis, vascular calcification, and myocardial calcification. Increases in phosphate levels are a pharmacodynamic effect of TRUSELTIQ .

Among 351 patients who received TRUSELTIQ across clinical trials], hyperphosphatemia was reported in 82% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 8 days (range 1-349). Phosphate binders were received by 83% of patients who received TRUSELTIQ. Monitor for hyperphosphatemia throughout treatment. Initiate phosphate lowering therapy when serum phosphate level is >5.5 mg/dL. For serum phosphate level >7.5 mg/dL, withhold TRUSELTIQ and initiate phosphate lowering therapy. Withhold, dose reduce, or permanently discontinue TRUSELTIQ based on duration and severity of hyperphosphatemia.

Embryo-Fetal Toxicity

• Based on findings in animal studies and its mechanism of action, TRUSELTIQ can cause fetal harm when administered to a pregnant woman. Oral administration of infigratinib to pregnant animals during the period of organogenesis caused malformations, fetal growth retardation, and embryo-fetal death at maternal exposures lower than the human exposure based on area under the curve (AUC) at the clinical dose of 125 mg.
• Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TRUSELTIQ and for 1 month after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with TRUSELTIQ and for 1 month after the final dose.

Adverse Reactions

Clinical Trials Experience

• Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
• The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to TRUSELTIQ as a single agent at 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles in 351 patients in Study CBGJ398X2204 and in patients with other advanced solid tumors or hematological malignancies. Among 351 patients who received TRUSELTIQ, 27% were exposed for 6 months or longer and 10% were exposed for greater than one year.

Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma

• The safety of TRUSELTIQ was evaluated in Study CBGJ398X2204, which included 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement .Patients were treated orally with TRUSELTIQ 125 mg once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles, until disease progression or unacceptable toxicity. The median duration of treatment was 5.5 months (range: 0.03 to 28.3 months).
• The median age of TRUSELTIQ treated patients was 53 years (range 23-81), 62% were females, and 72% were White.
• Serious adverse reactions occurred in 32% of patients receiving TRUSELTIQ. Serious adverse reactions in ≥2% of patients who received TRUSELTIQ included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient who received TRUSELTIQ and was due to sepsis.
• Permanent discontinuation due to an adverse reaction occurred in 15% of patients who received TRUSELTIQ. Adverse reactions requiring permanent discontinuation in ≥1% of patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.
• Dosage interruptions due to an adverse reaction occurred in 64% of patients who received TRUSELTIQ. Adverse reactions requiring dosage interruption in ≥5% of patients included hyperphosphatemia, hypercalcemia, palmar-plantar erythrodysesthesia syndrome, stomatitis, diarrhea, and blood creatinine increased.
• Dosage reductions due to an adverse reaction occurred in 60% of patients who received TRUSELTIQ. Adverse reactions requiring dosage reductions in ≥2% of patients who received TRUSELTIQ included hyperphosphatemia, stomatitis, palmar-plantar erythrodysesthesia syndrome, increased blood creatinine, increased lipase, hypercalcemia, and onycholysis.
• The most common (≥20%) adverse reactions were nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, vision blurred and vomiting. The most common laboratory abnormalities (≥20%) were increased creatinine, increased phosphate, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased alanine aminotransferase, increased lipase, increased calcium, decreased lymphocytes, decreased sodium, increased triglycerides, increased aspartate aminotransferase, increased urate, decreased platelets, decreased leukocytes, decreased albumin, increased bilirubin and decreased potassium.

TABLE 3 summarizes the adverse reactions in Study CBGJ398X2204. TABLE 4 summarizes select laboratory abnormalities in Study CBGJ398X2204.

Adverse Reactions (≥15%) in Patients Receiving TRUSELTIQ in Study CBGJ398X2204

Adverse Reactions (≥15%) in Patients Receiving TRUSELTIQ in Study CBGJ398X2204

Select Laboratory Abnormalities (≥10%) Worsening from Baseline in Patients Receiving TRUSELTIQ in Study CBGJ398X2204

Select Laboratory Abnormalities (≥10%) Worsening from Baseline in Patients Receiving TRUSELTIQ in Study CBGJ398X2204

Graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE 4.03). The denominator used to calculate the rate varied from 104 to 107 based on the number of patients with a baseline value and at least one post-treatment value. These laboratory abnormalities are values that reflect worsening from baseline. Graded per NCI CTCAE 4.03. a NCI CTCAE 4.03 does not define grades for increased phosphate. Laboratory value shift table categories were used to assess increased phosphorus levels (Grades ≥3 defined as ≥9mg/dL).

Postmarketing Experience

There is limited information regarding Infigratinib Postmarketing Experience in the drug label.

Drug Interactions

Effects of Other Drugs on TRUSELTIQ

Strong and Moderate CYP3A Inhibitors

Concomitant use of TRUSELTIQ with a strong or moderate CYP3A inhibitor may increase infigratinib plasma concentrations, which may increase the risk of adverse reactions. Avoid concomitant use of TRUSELTIQ with strong or moderate CYP3A inhibitors.

Strong and Moderate CYP3A Inducers

Concomitant use of TRUSELTIQ with a strong or moderate CYP3A inducer may decrease infigratinib plasma concentrations, which may reduce TRUSELTIQ anti-tumor activity. Avoid concomitant use of TRUSELTIQ with strong or moderate CYP3A inducers.

Gastric Acid Reducing Agents

The coadministration of TRUSELTIQ with a gastric acid reducing agent may decrease infigratinib plasma concentrations, which may reduce TRUSELTIQ anti-tumor activity.

Avoid concomitant use of TRUSELTIQ with proton pump inhibitors (PPIs), H2-antagonists, and locally-acting antacids. If coadministration of H2-antagonists or locally-acting antacids cannot be avoided, stagger administration of TRUSELTIQ.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Risk Summary

• Based on findings in animal studies and its mechanism of action TRUSELTIQ can cause fetal harm or loss of pregnancy when administered to a pregnant woman [ see Clinical Pharmacology (13.1) ]. There are no available data on the use of TRUSELTIQ during pregnancy. Oral administration of infigratinib to pregnant animals during the period of organogenesis at maternal exposures below the human exposure at the clinical dose of 125 mg resulted in malformations, fetal growth retardation, and embryo-fetal death (see Data). Advise pregnant women of the potential risk to a fetus.

• In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

• Once daily oral administration of infigratinib to pregnant rats during organogenesis resulted in an increase in embryo-fetal lethality at 10 mg/kg/day and reductions in fetal body weights at ≥3 mg/kg/day (<0.1 times the human exposure at the clinical dose of 125 mg). Fetal abnormalities (external, soft tissue, and skeletal) were increased at ≥1 mg/kg/day (<0.1 times the human exposure at the clinical dose of 125 mg). In the embryo-fetal portion of a rat fertility study, infigratinib decreased the mean number of embryos and increased nonviable embryos and post-implantation loss in females at 3 mg/kg/day.

• Once daily oral administration of infigratinib at ≥0.3 mg/kg/day to pregnant rabbits resulted in maternal toxicity and a corresponding reduction in fetal body weights.

Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Infigratinib in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Infigratinib during labor and delivery.

Nursing Mothers

Risk Summary

• There are no data on the presence of infigratinib or its metabolites in human milk, or their effects on either the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children from TRUSELTIQ, advise women not to breastfeed during treatment and for 1 month after the final dose.

Pediatric Use

• The safety and effectiveness of TRUSELTIQ in pediatric patients have not been established.

Geriatic Use

• Of the 351 patients treated with TRUSELTIQ in clinical studies, 33% were 65 years or older, and 10% were 75 years or older. No overall differences in safety or effectiveness of TRUSELTIQ have been observed between patients 65 years of age and older and younger adult patients.

Gender

There is no FDA guidance on the use of Infigratinib with respect to specific gender populations.

Race

There is no FDA guidance on the use of Infigratinib with respect to specific racial populations.

Renal Impairment

• Reduce the dosage of TRUSELTIQ for patients with mild or moderate renal impairment (creatinine clearance [CLcr] 30 to 89 mL/min estimated by Cockcroft-Gault).
• The recommended dosage of TRUSELTIQ has not been established for patients with severe renal impairment (CLcr < 30 mL/min) or for patients with end-stage renal disease receiving intermittent hemodialysis.

Hepatic Impairment

• Reduce the dosage of TRUSELTIQ for patients with mild (total bilirubin > upper limit of normal [ULN] to 1.5 × ULN or AST > ULN) or moderate (total bilirubin >1.5 to 3 × ULN with any AST) hepatic impairment. The recommended dosage of TRUSELTIQ has not been established in patients with severe (total bilirubin > 3 × ULN with any AST) hepatic impairment.

Females of Reproductive Potential and Males

TRUSELTIQ can cause fetal harm when administered to a pregnant woman.

Pregnancy Testing

Verify pregnancy status of females of reproductive potential prior to initiating TRUSELTIQ.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with TRUSELTIQ and for 1 month after the final dose.

Males

Advise males that are partnered with females of reproductive potential to use effective contraception during treatment with TRUSELTIQ and for 1 month after the final dose.

Immunocompromised Patients

There is no FDA guidance one the use of Infigratinib in patients who are immunocompromised.

Animal Toxicity Data

In rat and dog repeat-dose toxicity studies ≥13 weeks in duration, animals displayed toxicities in bones (rats and dogs) and teeth (rats) at exposures lower than the human exposure at the clinical dose of 125 mg. Once daily oral administration of infigratinib in a 13-week rat study resulted in incisor degeneration (degeneration of enamel and loss of ameloblast layer). Once daily oral administration of infigratinib in a 26-week rat study resulted in bone effects (decreased bone strength consistent with decreases in total bone mineral density in lumbar vertebral bodies). Once daily oral administration of infigratinib in a 39-week dog study resulted in increased growth plate thickness and fractures associated with increased physeal thickness, focal mixed reaction, and bone loss.

Administration and Monitoring

Administration

Patient Selection

Select patients for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma with TRUSELTIQ based on the presence of an FGFR2 fusion or rearrangement, as detected by an FDA-approved test . Information on FDA-approved test(s) for the detection of FGFR2 fusions or rearrangements in cholangiocarcinoma is available at: http://www.fda.gov/CompanionDiagnostics.

Recommended Dosage

The recommended dosage of TRUSELTIQ is 125 mg (one 100 mg capsule and one 25 mg capsule) orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles. Continue treatment until disease progression or unacceptable toxicity.

• Instruct patients to take TRUSELTIQ on an empty stomach at least 1 hour before or 2 hours after food at approximately the same time each day. Instruct patients to swallow capsules whole with a glass of water. Advise patients to not crush, chew, or dissolve capsules.
• If a dose of TRUSELTIQ is missed by ≥4 hours or if vomiting occurs, instruct patients to resume the regular daily dose schedule for TRUSELTIQ the next day.

Dose Modification for Adverse Reactions

The recommended dose reductions for adverse reactions are listed in Table 1.

Recommended Dose Reduction for TRUSELTIQ for Adverse Reactions

The recommended dosage modifications for adverse reactions are provided in Table 2 .

Recommended Dosage Modifications for TRUSELTIQ Adverse Reactions

Recommended Dosage Modifications for TRUSELTIQ Adverse Reactions

Dose Modification for Moderate Hepatic Impairment

Avoid coadministration of a proton pump inhibitor (PPI), a histamine-2 (H2) receptor antagonist, or a locally-acting antacid with TRUSELTIQ .If coadministration cannot be avoided:

• H2-antagonist: Separate administration of TRUSELTIQ by 2 hours before or 10 hours after.
• Locally-acting antacid: Separate administration of TRUSELTIQ by 2 hours before or after.

==== Recommended Dosage for Mild and Moderate Renal Impairment The recommended dosage of TRUSELTIQ for patients with mild to moderate renal impairment (creatinine clearance 30 to 89 mL/min, estimated by Cockcroft-Gault) is 100 mg once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.

Recommended Dosage for Mild and Moderate Hepatic Impairment

The recommended dosage of TRUSELTIQ for patients with mild (total bilirubin > upper limit of normal [ULN] to 1.5 × ULN or AST > ULN ) or moderate hepatic impairment (total bilirubin >1.5 to 3 × ULN with any AST) is as follows .

• Mild Hepatic Impairment: 100 mg once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.
• Moderate Hepatic Impairment: 75 mg once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.

Monitoring

• Monitor serum phosphate weekly.
• Monitor for hyperphosphatemia throughout treatment. Initiate phosphate lowering therapy when serum phosphate level is >5.5 mg/dL. For serum phosphate level >7.5 mg/dL, withhold TRUSELTIQ and initiate phosphate lowering therapy. Withhold, dose reduce, or permanently discontinue TRUSELTIQ based on duration and severity of hyperphosphatemia.

IV Compatibility

There is limited information regarding the compatibility of Infigratinib and IV administrations.

Overdosage

There is limited information regarding Infigratinib overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Infigratinib Pharmacology in the drug label.

Mechanism of Action

• Infigratinib is a small molecule kinase inhibitor of FGFR with IC 50 values of 1.1, 1, 2, and 61 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.
• The major human metabolites of infigratinib, BHS697 and CQM157, have similar in vitro binding affinities for FGFR1, FGFR2, and FGFR3 compared to infigratinib.
• Infigratinib inhibited FGFR signaling and decreased cell proliferation in cancer cell lines with activating FGFR amplifications, mutations, or fusions.
• Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Infigratinib had anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR2 or FGFR3 alterations, including two patient-derived xenograft models of cholangiocarcinoma that expressed FGFR2-TTC28 or FGFR2-TRA2B fusions.
• Infigratinib demonstrated brain-to-plasma concentration ratios (based on AUC 0-inf) of 0.682 in rats after a single oral dose.

Structure

There is limited information regarding Infigratinib Structure in the drug label.

Pharmacodynamics

Serum Phosphate

• TRUSELTIQ increased serum phosphate levels due to FGFR inhibition. Serum phosphate increased with increasing exposures across the dose range of 20 to 150 mg once daily (0.16 to 1.2 times the approved recommended dosage), with increased risk of hyperphosphatemia with higher exposure to TRUSELTIQ.

Cardiac Electrophysiology

• At the recommended dosing regimen, TRUSELTIQ does not result in a large mean increase (i.e., >20 msec) in the QTc interval. The QT effect of infigratinib at higher exposures associated with CYP3A inhibition has not been studied.

Pharmacokinetics

• The infigratinib pharmacokinetic parameters are presented following administration of the approved recommended dosage in cholangiocarcinoma patients, unless otherwise specified.
• The mean (coefficient of variation [%CV]) steady-state maximum plasma concentration (C max) and area under the curve over a dosing interval (AUC 0 24h) of infigratinib and active metabolites, BHS697 and CQM157, are presented in Table 5 .

Mean (%CV) Exposure of Infigratinib and Active Metabolites

Infigratinib C max and AUC increased more than proportionally across the dose range of 5 to 150 mg (0.04 to 1.2 times the approved recommended dose). Steady state was achieved within 15 days and the mean accumulation ratio was 8- and 5-fold for C max and AUC, respectively.

Absorption

• Median (range) time to achieve peak infigratinib plasma concentration (t max) was 6 hours (2 to 7 hours) at steady state.

Effect of Food

Following administration of TRUSELTIQ with a high-fat and high-calorie meal (800 to 1,000 calories with approximately 50% of total caloric content of the meal from fat) in healthy subjects, the mean AUC inf of infigratinib increased by 80%-120% and C max increased by 60%-80%, the median T max shifted from 4 hours to 6 hours. Following administration of TRUSELTIQ with a low-fat low-calorie meal (approximately 330 calories with 20% of total caloric content of the meal from fat), the mean AUC inf of infigratinib increased by 70%, C max increased by 90%, and the median T max did not change.

=Distribution

The geometric mean (CV%) apparent volume of distribution of infigratinib was 1600 L (33%) at steady state. The mean infigratinib protein binding was 96.8%, primarily to lipoprotein, and was dependent of drug concentration.

Elimination

The geometric mean (CV%) total apparent clearance (CL/F) of infigratinib was 33.1 L/h (59%) at steady state. The geometric mean (CV%) terminal half-life of infigratinib was 33.5 h (39%) at steady state.

Metabolism

Infigratinib is predominantly metabolized by CYP3A4 (~94%) and to a lesser extent by FMO3 (6%) in vitro. The major drug-related moiety in plasma was unchanged infigratinib (38% of dose) in a human [ 14C] mass balance study, followed by two active metabolites, BHS697 and CQM157 (each at >10% of dose). BHS697 is mainly metabolized by CYP3A4 and CQM157 is metabolized through both Phase I and Phase II biotransformation pathways. BHS697 and CQM157 contribute about 16% to 33% and 9% to 12% of overall pharmacologic activity, respectively.

Excretion

After a single oral 125 mg dose of radiolabeled infigratinib in healthy subjects, approximately 77% of the dose was recovered in feces (3.4% as unchanged) and 7.2% in urine (1.9% as unchanged).

Specific Populations

No clinically significant differences in the systemic exposure of infigratinib were observed based on age (19 86 years), sex, race/ethnicity (White 70.7%, Black 15.4%, and Asian 8%), or body weight (36.4-169 kg).

Patients with Renal Impairment

The relative potency adjusted steady state AUC of infigratinib plus its active metabolites (BHS697, CQM157) in plasma increased by 32% and 37% in patients with mild (creatinine clearance [CLcr] 60 to 89 mL/min estimated by Cockcroft-Gault) and moderate renal impairment (CLcr 30 to 59 mL/min), respectively, relative to patients with normal renal function (CLcr ≥ 90 mL/min). The effect of severe renal impairment (CLcr < 30 mL/min) or renal dialysis in end-stage renal disease on infigratinib exposure is unknown.

Patients with Hepatic Impairment

The relative potency adjusted steady state AUC of infigratinib plus its active metabolites (BHS697, CQM157) in plasma increased by 47%-62% and 99% in patients with mild (total bilirubin > upper limit of normal [ULN] to 1.5 × ULN or AST > ULN) and moderate hepatic impairment (total bilirubin > 1.5 to 3 × ULN with any AST), respectively, relative to patients with normal hepatic function (total bilirubin ≤ ULN and AST ≤ ULN). The effect of severe hepatic impairment (total bilirubin > 3 × ULN with any AST) on infigratinib exposure is unknown.

Drug Interaction Studies

Clinical Studies

*Strong CYP3A Inhibitors:

• Coadministration of multiple doses of itraconazole (strong CYP3A inhibitor) increased infigratinib AUC 0-inf by 622% and C max by 164%, increased BHS697 AUC 0-inf by 174%, and decreased CQM157 C max by 69%, respectively].

Strong CYP3A Inducers:

*Coadministration of multiple doses of rifampin (strong CYP3A inducer) decreased infigratinib AUC 0-inf by 56% and C max by 44%, decreased BHS697 AUC 0-inf by 65% and C max by 27%, and decreased CQM157 AUC 0-inf by 76% and C max by 50%, respectively.

Gastric Acid-Lowering Agents:

• Coadministration of multiple doses of lansoprazole (proton pump inhibitor) decreased infigratinib AUC 0-inf by 45% and C max by 49%, decreased BHS697 AUC 0-inf by 32% and C max by 44%, and decreased CQM157 AUC 0-inf by 72% and C max by 55%, respectively.

CYP3A4 Substrates:

• No clinically significant differences in pharmacokinetics of midazolam (sensitive CYP3A4 substrate) were observed when co-administered with TRUSELTIQ.

In Vitro Studies

Cytochrome P450 Enzymes:

• Infigratinib does not induce CYP1A2, CYP2B6, CYP2C9, or CYP3A4. Infigratinib, BHS697, and CQM157 do not inhibit major CYP450 isozymes at clinically relevant concentrations.

Transporter Systems:

• Infigratinib inhibits MATE1 and BCRP. Infigratinib has a low potential to inhibit P-gp, BSEP, OCT1, OCT2 and MATE-2K at clinically relevant concentrations. Infigratinib is a substrate for P-gp and BCRP. The metabolites BHS697 and CQM157 have a low potential to inhibit OATP1B1, OATP1B3, P-gp, or BCRP at clinically relevant concentrations.
• The effect of these metabolites to inhibit MATE or OCT at clinically relevant concentrations is unknown.

Nonclinical Toxicology

There is limited information regarding Infigratinib Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Infigratinib Clinical Studies in the drug label.

How Supplied

There is limited information regarding Infigratinib How Supplied in the drug label.

Storage

There is limited information regarding Infigratinib Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Infigratinib |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Infigratinib |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Infigratinib Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Infigratinib interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

TRUSELTIQ

Look-Alike Drug Names

There is limited information regarding Infigratinib Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.